1. Scrip
  2. >>Business

Cipla Evaluates US Portfolio Tucks, Generic Advair Studies Progress

 
• By Anju Ghangurde

Alongside a build-up in the US, Cipla is keeping a sharp eye on its “profitability profile” in this market and expects to rationalize products that don’t fit the bill. But it remains on track to establishing a respiratory franchise in key regulated markets, with generic Advair studies moving forward in the US.

Jigsaw
CIPLA AIMS TO MAINTAIN A HEALTHY PROFITABILITY PROFILE

After implementing a string of operational fixes and tweaks in its European and emerging markets businesses, Cipla Ltd. is now evaluating plans to fine-tune its US product portfolio with an eye on margins, among other factors. (Also see "Operational Fixes At Cipla But All Eyes On Generic Advair" - Scrip, 25 May, 2016.)

Cipla, which hopes to grow its US business towards a “billion dollar enterprise”, said that it is taking “a deeper look” into its marketed portfolio there at the “margin level” and at the “relative burden” on its manufacturing and supply chain infrastructure, to see

More from Business

More from Scrip

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Atara Does An About Face As FDA Lifts Ebvallo Hold

 
• By Alaric DeArment

The biotech said it will have a type A meeting with the agency to resubmit for the cell therapy’s approval in EBV+ PTLD.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.